Indoco Remedies Limited has informed the Exchange regarding a press release dated December 11, 2025, titled "Indoco receives EIR from the USFDA for its API manufacturing facility at Patalganga ".
INDOCO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Indoco Remedies Limited has received an Establishment Inspection Report (EIR) from the USFDA for its Active Pharmaceutical Ingredient (API) manufacturing facility located at Patalganga. An EIR is issued by the USFDA after completing an inspection and indicates that the audit of the facility has been formally closed. Receiving an EIR is generally considered a positive regulatory outcome, suggesting the facility met acceptable compliance standards. This is significant for Indoco as USFDA-approved API facilities are important for supplying regulated markets like the United States.
Positive for shareholders — EIR clearance strengthens Indoco's regulatory standing with the USFDA and supports its ability to supply APIs to the US market, which could boost export revenues and investor confidence.